產(chǎn)品詳情
簡單介紹：
Anti-CDR2抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-CDR2抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-CDR2
Cat. Number:
Anti-CDR2抗體KL-6296R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
CDR2 (cerebellar degeneration-related protein 2), also referred to as Yo or CDR62, is a 545 amino acid protein that is Anti-CDR2抗體associated with the development of paraneoplastic cerebellar degeneration (PCD). PCD, an immune-mediated syndrome, belongs to a heterogeneous group of rare paraneoplastic neurologic disorders affecting the neurological system. PCD is characterized by subacute cerebellar ataxia and occurs mainly in patients with ovarian, uterine, fallopian tube or breast cancer. Patients with ovarian or breast cancer develop an immune response against cancer cell-expressed CDR2 and Purkinje neuron-expressed CDR2. The presence of the anti-CDR2 antibody in patients with PCD symptoms warrants an aggressive approach to diagnosis and treatment of the underlying cancer.
Also known as:
CDR 2; CDR 62; Anti-CDR2抗體CDR2; CDR2_HUMAN; CDR62; Cerebellar degeneration related protein 2; Cerebellar degeneration related protein; Cerebellar degeneration-related protein 2; Major Yo paraneoplastic antigen; Paraneoplastic cerebellar degeneration associated antigen; Paraneoplastic cerebellar degeneration-associated antigen; PCD 17; PCD17; Yo antibody; Yo paraneoplastic antigen.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Cow, Horse, .
●
Immunogen: KLH conjugated synthetic peptide derived from human CDR2/PCD17.
●
Predicted Molecular Anti-CDR2抗體Weight: 52kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working Anti-CDR2抗體dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working Anti-CDR2抗體dilutions must be determined by the end user.
kl726Hu01 **細(xì)胞銜接蛋白(Lnk)多克隆抗體 Polyclonal Antibody to Lymphocyte Adaptor Protein (Lnk)
kl871Hu01 含普列克底物同源物域家族A成員1(PLEKHA1)多克隆抗體 Polyclonal Antibody to Pleckstrin Homology Domain Containing Family A, Member 1 (PLEKHA1)
kl540Mu01 蓬亂蛋白Dsh同源物1(DVL1)多克隆抗體 Polyclonal Antibody to Dishevelled, Dsh Homolog 1 (DVL1)
kl707Hu01 H2A組蛋白家族成員Y(H2AFY)多克隆抗體 Polyclonal Antibody to H2A Histone Family, Member Y (H2AFY)
kl934Hu01 Numb同源物(NUMB)多克隆抗體 Polyclonal Antibody to Numb Homolog (NUMB)
kl934Mu01 Numb同源物(NUMB)多克隆抗體 Polyclonal Antibody to Numb Homolog (NUMB)
kl243Hu01 非轉(zhuǎn)移細(xì)胞3表達(dá)NM23A蛋白(NME3)多克隆抗體 Polyclonal Antibody to Non Metastatic Cells 3, Protein NM23A Expressed In (NME3)
kl243Mu01 非轉(zhuǎn)移細(xì)胞3表達(dá)NM23A蛋白(NME3)多克隆抗體 Polyclonal Antibody to Non Metastatic Cells 3, Protein NM23A Expressed In (NME3)
kl276Ra01 O-巖藻糖肽3-β-N-乙酰氨基葡萄糖轉(zhuǎn)移酶(RFNG)多克隆抗體 Polyclonal Antibody to O-Fucosylpeptide-3-Beta-N-Acetylglucosaminyltransferase (RFNG)
kl296Hu01 含核苷酸結(jié)合寡聚化域蛋白1(NOD1)多克隆抗體 Polyclonal Antibody to Nucleotide Binding Oligomerization Domain Containing Protein 1 (NOD1)
kl007Hu01 側(cè)支發(fā)芽因子同源物3(SPRY3)多克隆抗體 Polyclonal Antibody to Sprouty Homolog 3 (SPRY3)
kl007Mu01 側(cè)支發(fā)芽因子同源物3(SPRY3)多克隆抗體 Polyclonal Antibody to Sprouty Homolog 3 (SPRY3)
kl007Ra01 側(cè)支發(fā)芽因子同源物3(SPRY3)多克隆抗體 Polyclonal Antibody to Sprouty Homolog 3 (SPRY3)
kl008Hu01 側(cè)支發(fā)芽因子同源物2(SPRY2)多克隆抗體 Polyclonal Antibody to Sprouty Homolog 2 (SPRY2)
kl008Mu01 側(cè)支發(fā)芽因子同源物2(SPRY2)多克隆抗體 Polyclonal Antibody to Sprouty Homolog 2 (SPRY2)
kl008Ra01 側(cè)支發(fā)芽因子同源物2(SPRY2)多克隆抗體 Polyclonal Antibody to Sprouty Homolog 2 (SPRY2)
kl298Hu01 CD2關(guān)聯(lián)蛋白(CD2AP)多克隆抗體 Polyclonal Antibody to CD2 Associated Protein (CD2AP)
